Understanding decisions about antibiotic prescribing in ICU: an application of the Necessity Concerns Framework

Alyssa M Pandolfo, Robert Horne, Yogini Jani, Tom W Reader, Natalie Bidad, David Brealey, Virve I Enne, David M Livermore, Vanya Gant, Stephen J Brett, INHALE WP2 Study Group

ABSTRACT
Background Antibiotics are extensively prescribed in intensive care units (ICUs), yet little is known about how antibiotic-related decisions are made in this setting. We explored how beliefs, perceptions and contextual factors influenced ICU clinicians’ antibiotic prescribing.

Methods We conducted four focus groups and 34 semistructured interviews with clinicians involved in antibiotic prescribing in four English ICUs. Focus groups explored factors influencing prescribing, whereas interviews examined decision-making processes using two clinical vignettes. Data analysis used thematic analysis, applying the Necessity Concerns Framework.

Results Clinicians’ antibiotic decisions were influenced by their judgement of the necessity for prescribing/not prescribing, relative to their concerns about potential adverse consequences. Antibiotic necessity perceptions were strongly influenced by beliefs that antibiotics would protect patients from deterioration and themselves from the ethical and legal consequences of undertreatment. Clinicians also reported concerns about prescribing antibiotics. These generally centred on antimicrobial resistance; however, protecting the individual patient was prioritised over these societal concerns. Few participants identified antibiotic toxicity concerns as a key influence. Clinical uncertainty often complicated balancing antibiotic necessity against concerns. Decisions to start or continue antibiotics often represented ‘errone on the side of caution’ as a protective response in uncertainty. This approach was reinforced by previous experiences of negative consequences (‘being burnt’) which motivated prescribing ‘just in case’ of an infection. Prescribing decisions were also context-dependent, exemplified by a lower perceived threshold to prescribe antibiotics out-of-hours, input from external team members and local prescribing norms.

Conclusion Efforts to improve antibiotic stewardship should consider clinicians’ desire to protect with a prescription. Rapid molecular microbiology, with appropriate communication, may diminish clinicians’ fears of not prescribing or of using narrower-spectrum antibiotics.

INTRODUCTION

Intensive care units (ICUs) are unique environments where clinicians often make antibiotic decisions under diagnostic uncertainty and with high-stakes consequences. During decision-making, intensivists must balance heightened priorities of patients’ needs with antimicrobial stewardship (AMS) initiatives; how ICU doctors navigate these trade-offs remains poorly understood.

Critical care patients frequently exhibit ‘traditional’ signs of infection (eg, fever) even when no infection is present; consequently differentiating infection from non-infectious conditions is challenging. Furthermore, infections may be viral rather than bacterial, with only the latter requiring antibiotics. Undertreating bacterial infections or delaying antibiotics in ICU may increase the risk of mortality; conversely, unnecessary therapy increases the risk of antibiotic-related side effects, including adverse drug reactions and infection with Clostridium (Clostridioides) difficile, and promoting antimicrobial resistance (AMR).

The development of AMR is of particular concern in ICU. Many patients have multiple comorbidities, histories of frequent hospital admissions, long hospital and ICU stays, multiple prior antibiotic courses, and complex physiologies; these factors can lead to underdosing and overdosing and are ideal circumstances for antibiotic toxicity and AMR development. These risks are compounded by invasive device usage, high broad-spectrum antibiotic exposure and ICU treatment intensity. Consequently, intensivists have seen an increasing prevalence of resistance and treatments failing due to AMR.
Accordingly, antibiotic decisions have high levels of consultant intensivist and microbiologist involvement, and ICU-specific AMS programmes have been developed. Yet up to 70% of ICU patients receive antimicrobial therapy, despite up to half having no confirmed infection.

Outside the ICU, studies have identified the importance of clinicians’ beliefs about their prescribing’s consequences, AMR perceptions, and social and professional influences. However, these studies have variously excluded intensivists, combined ICU and non-ICU wards, or did not specify which wards were included.

The Necessity Concerns Framework (NCF) may help to understand antibiotic decision-making. Extensively used to understand patients’ medication adherence, NCF posits that decisions to start and continue with treatments are influenced by how individuals judge the necessity for treatment relative to their concerns about the actual or potential adverse consequences of taking it.

Like Hulscher and colleagues, we applied a social and behavioural approach investigating clinicians’ perspectives of antibiotic decision-making (‘clinician perceptions’) and the social and environmental aspects surrounding these perceptions (‘contextual factors’). We explore these factors’ influence on ICU antibiotic decision-making, interpreting our findings using NCF.

METHODS

This research is part of the INHALE programme (ISRCTN16483855) investigating molecular diagnostic utility for pneumonias in ICU. A randomised controlled trial is being conducted whereby patients with suspected pneumonias are randomised to receive either standard care or decision-making support from a point-of-care molecular diagnostic test. A behavioural evaluation examines antibiotic decision-making and clinicians’ willingness to adopt molecular tests. Before the trial, we strove to understand how ICU antibiotic decisions were made.

This study is reported following the Standards for Reporting Qualitative Research guidelines. It used focus groups and vignette-based interviews (VBIs) and followed a contextualist approach positing that the external context affects individuals’ interpretation of their experiences. All participants provided informed consent.

Study design

Focus groups explored contextual factors perceived to influence antibiotic decisions. Through these discussions, clinicians shared and compared their prescribing attitudes and experiences, allowing exploration of a range of perspectives (see online supplemental table S1 for topic guide).

Interviews investigated antibiotic decision-making processes. These used clinical vignettes depicting hypothetical but realistic scenarios at key decision points (see online supplemental table S2 for vignettes and interview guides). Individuals applied their expertise and experience to determine a course of action based on provided information, followed by a wide-ranging and detailed discussion around raised issues. Cognitive processes elicited during VBIs simulate real-world decision-making, and researchers can compare participants’ responses and systematically reconstruct decision-making processes.

Sample and setting

This research occurred in the ICUs of four English hospitals (see table 1 for the characteristics). We chose these sites due to their differences in patient populations and in general prevalence of resistant bacteria. Convenience sampling was used; clinicians participated whenever they could spare time from clinical duties. Focus groups were prescheduled, whereas VBIs were opportunistic. NB, YJ and DB recruited participants through local promotion; NB and YJ have clinical pharmacy backgrounds and DB is an ICU consultant at a participating site.

In UK ICUs, consultants (‘attending’ level permanent staff with usually over 10 years of experience) make most antibiotic decisions, aided by clinical microbiologists, typically consultant level. ICUs are ‘closed units’—consultant intensivists have ultimate decision-making power for patients. Members from teams like microbiology and surgery can give recommendations but cannot change aspects of the patient’s management without consultant intensivist permission. ICU middle-grade (5–7 years of experience) and early-grade (up to 4 years of experience) trainees occasionally make antibiotic decisions, usually in urgent out-of-hours settings. Pharmacists aid with dosing and monitoring antibiotics, including choice and treatment durations.

All staff involved in ICU antibiotic prescribing could participate in focus groups; recognising that decision-making involves the team, non-prescribers were included. VBI participants were individuals who would actively prescribe on ICU (ie, consultant intensivists and trainees).

Data collection

NB and YJ conducted all focus groups and VBIs. Focus groups were semi-structured and began with ‘What factors do you think influence your decisions around antimicrobial prescribing on your ICU?’ The moderators used predetermined follow-up prompts about contextual factors influencing prescribing. One focus group was conducted at each site; three were face-to-face and one was a teleconference. Four focus groups were deemed sufficient as previous research found that all prevalent themes could be identified in three. Focus groups lasted between 23 and 45 min and were undertaken between August and September 2018.
### Table 1  Participating hospital and intensive care unit characteristics

<table>
<thead>
<tr>
<th></th>
<th>Hospital 1</th>
<th>Hospital 2</th>
<th>Hospital 3</th>
<th>Hospital 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hospital type</strong></td>
<td>Tertiary referral hospital</td>
<td>Specialist paediatric hospital</td>
<td>Private hospital</td>
<td>Academic secondary care hospital; also teaching and tertiary</td>
</tr>
<tr>
<td><strong>Location</strong></td>
<td>London, UK</td>
<td>London, UK</td>
<td>London, UK</td>
<td>Norfolk, UK</td>
</tr>
<tr>
<td><strong>Hospital bed number</strong></td>
<td>720</td>
<td>425</td>
<td>118</td>
<td>1200</td>
</tr>
<tr>
<td><strong>ICU bed number</strong></td>
<td>35</td>
<td>27</td>
<td>7</td>
<td>20</td>
</tr>
<tr>
<td><strong>Hospital admissions (patients per year)</strong></td>
<td>~160000</td>
<td>43218</td>
<td>9926</td>
<td>85728</td>
</tr>
<tr>
<td><strong>ICU admissions (patients per year)</strong></td>
<td>3000</td>
<td>Paediatric ICU: 900</td>
<td>Neonatal ICU: 450</td>
<td>264</td>
</tr>
<tr>
<td><strong>ICU patient characteristics</strong></td>
<td>A surgical/medical adult unit. Approximately half of the cases are admitted following major elective surgery; the other half comprise emergency medical and surgical patients. The unit specialises in the care of patients undergoing oncological treatments and patients undergoing extensive gastrointestinal, gynaecological and maxillofacial surgery. The active emergency department results in several unselected admissions from the local community.</td>
<td>Paediatric ICU: children and young people needing critical care for medical or surgical conditions (e.g., oncology, neurology, renal, respiratory). Neonatal ICU: critically ill premature infants and babies up to 6 months old with complex medical and surgical problems (e.g., necrotising enterocolitis, tracheo-oesophageal fistulae).</td>
<td>All adult ages; elective surgical cases, all specialties medical (cardiac, respiratory, oncology); long-term intensive critical care; slow respiratory wean/rehabilitation patients.</td>
<td>Elective and emergency surgical cases.</td>
</tr>
<tr>
<td><strong>ICU antibiotic prescribers</strong></td>
<td>Consultants with clinical microbiology advice; pharmacist prescribers; early-career and middle-grade trainees can prescribe out-of-hours.</td>
<td>Paediatric ICU consultants and middle-grade staff prescribe. Advice is given by infectious disease and microbiology consultants, and pharmacists.</td>
<td>Consultants with clinical microbiology advice; middle-grade trainees can prescribe out-of-hours.</td>
<td>Consultants with clinical microbiology advice; early-career and middle-grade trainees can prescribe out-of-hours. No pharmacist prescribers at present.</td>
</tr>
<tr>
<td><strong>Hospital antimicrobial stewardship programmes</strong></td>
<td>Freely available, electronic antimicrobial guidelines (including sepsis guidelines) as well as a dedicated multidisciplinary team of pharmacists and microbiologists monitoring antimicrobial prescription with bedside consults as necessary.</td>
<td>Antibiotic stewardship programmes guide all antibiotic prescriptions, including the intensive care units. Regularly audit and report Trust and national governance data.</td>
<td>Freely available, electronic antimicrobial guidelines (including sepsis guidelines) as well as a dedicated multidisciplinary team of pharmacists and microbiologists monitoring antimicrobial prescription with bedside consults as necessary.</td>
<td>All antibiotics required to have an indication and review date (at least 48 hours after initial prescription). Trust guidelines (including sepsis guidelines).</td>
</tr>
<tr>
<td><strong>ICU antimicrobial stewardship programmes</strong></td>
<td>A 5-day-per-week consultant clinical microbiologist who reviews every patient with an ICU doctor. A 24/7 on-call clinical microbiologist to discuss antibiotic choices, a prescribing algorithm, an antimicrobial pharmacist, an embedded infection control nurse and an antimicrobial formulary.</td>
<td>Consultant clinical microbiologists, infectious diseases doctors and virologists who review every patient with an ICU doctor at least twice a week. Antimicrobial stewardship pharmacists attend the majority of ward rounds.</td>
<td>Consultant clinical microbiologist, clinical pharmacist and infection control lead nurse do weekly stewardship rounds. A 24/7 on-call microbiologist to discuss antibiotic choices.</td>
<td>A 5-day-per-week consultant clinical microbiologist who reviews every patient with an ICU doctor. A 24/7 on-call microbiologist to discuss antibiotic choices. Trust guidelines and microbiology advice.</td>
</tr>
</tbody>
</table>

ICU, intensive care unit.
Semistructured interviews explored decision-making processes using two vignettes. Vignette 1 related to whether to start a patient on antibiotics, whereas vignette 2 depicted a patient currently on antibiotics where clinicians could choose to continue, change or stop antibiotics. Both patients had lower respiratory tract infections; these are common to ICU and are associated with diagnostic uncertainty. These scenarios had no ‘correct’ answers; rather, their purpose was to encourage reflection on decision-making processes. Five non-participating consultant intensivists pilot-tested the vignettes to ensure they were realistic and included sufficient information.

Paediatric clinicians were given analogous vignettes depicting children; otherwise, the same interview guides were used for all participants. VBIIs were conducted face-to-face in each ICU, lasted between 7 and 40 min, and occurred between August and December 2018. Interviews and coding were iterative, with interviews conducted until data saturation (three consecutive interviews resulting in redundant information).26

Data analysis
All focus groups and interviews were audio-recorded, anonymised, professionally transcribed and entered into NVivo V.12. AMP (research psychologist), NB and YJ verified transcript accuracy. Data were first analysed using inductive thematic analysis, with themes constructed at a semantic level summarising content explicitly discussed by multiple clinicians.27

Data were open-coding, with codes refined and themes formed with input from the multidisciplinary team (see online supplemental table S3 for disciplines). We then adopted a deductive approach interpreting the generated themes using NCF.28 For instance, themes related to clinicians’ beliefs of antibiotic importance were classified as necessity perceptions. As focus group participants discussed their perceptions and VBI participants mentioned contextual factors, we treated both data sources as equally important and triangulated our findings between them.29

AMP conducted analyses, aided by NB, following Braun and Clarke’s10 approach: data familiarisation, generating codes, searching for themes, reviewing and defining themes, and writing the report.

RESULTS
Audio recording duration was approximately 2.6 hours for focus groups and 9 hours for VBIIs. Focus group participants largely agreed with each other; there were few if any points of tension. Table 2 shows participants’ characteristics.

Our overarching finding was that clinicians favoured starting or continuing antibiotics in uncertainty. Prescribing antibiotics was often perceived as necessary to protect patients and clinicians from deleterious immediate consequences. If clinicians were uncertain whether antibiotics were required, they favoured ‘errning on the side of caution’:

the easy default is to give an antibiotic and if you’re confident or overconfident or deluded or whatever, you sometimes hold. —P52, consultant, hospital 1, focus group

it’s 48 hours [until culture results come back]. I think you’ve got more tendency to try and prescribe something [antibiotics] just because it’s going to be... Until you know exactly there’s nothing going on. —P47, early-career trainee, hospital 4, VBI

I think they [intensivists] would be always being errning on the side of caution, you wouldn’t even stop it [antibiotics] if there is any suspicion of risk. —P40, pharmacist, hospital 2, focus group

Clinicians’ perceptions of antibiotic necessity outweighing antibiotic-related concerns underscore errning on the side of caution. Contextual factors also influenced this inclination to prescribe in uncertainty. We describe both themes in the following sections.

Clinician perceptions of antibiotic necessity outweighing concerns
Perceptions of the necessity to prescribe were related to beliefs that, in uncertainty, antibiotics provide protection for patients and clinicians. Clinicians were

<table>
<thead>
<tr>
<th>Focus groups</th>
<th>Vignette-based interviews</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>Total: 26</td>
</tr>
<tr>
<td>Hospital 1: 11</td>
<td></td>
</tr>
<tr>
<td>Hospital 2*: 5</td>
<td></td>
</tr>
<tr>
<td>Hospital 3: 5</td>
<td></td>
</tr>
<tr>
<td>Hospital 4: 5</td>
<td></td>
</tr>
</tbody>
</table>

| Participants’ roles† | Hospital 1: 5 ICU consultants, 2 ICU middle-grade trainees, 1 ICU early-career trainee, 1 clinical microbiologist, 1 ICU pharmacist, 1 health psychologist. |
| Hospital 2: 1 ICU consultant, 3 ICU pharmacists, 1 infectious diseases consultant. |
| Hospital 3: 2 ICU middle-grade trainees, 2 ICU pharmacists, 1 nurse. |
| Hospital 4: 2 ICU consultants, 1 ICU middle-grade trainee, 1 clinical microbiologist, 1 ICU pharmacist. |

| Total: 34‡ | Hospital 1: 4 ICU consultants, 4 ICU middle-grade trainees, 3 ICU early-career trainees. |
| Hospital 2: 3 ICU consultants, 7 ICU middle-grade trainees. |
| Hospital 3: 2 ICU consultants, 5 ICU middle-grade trainees. |
| Hospital 4: 2 ICU consultants, 4 ICU early-career trainees. |

*All clinicians from hospital 2 care for paediatric patients; the remainder treat adults.†Interviews occurred individually except in one case where one early-career trainee and one middle-grade trainee were interviewed together.‡One consultant from hospital 1 and one from hospital 4 participated in both the focus groups and interviews.§Two middle-grade trainees were only able to complete vignette 1 owing to clinical pressures on the unit.†ICU, intensive care unit.

aware of and concerned about AMR, whereas they seldom mentioned concerns about the potential for antibiotics resulting in patient harm as key considerations. Concerns about antibiotic harm (individual and societal) were rarely prioritised to a degree where they outweighed perceived necessity, enabling clinicians to be brave by withholding or stopping antibiotics. This encouraged antibiotic prescription and continuation in an approach characterised by erring on the side of caution. Table 3 shows supporting quotes.

**Antibiotic necessity: prescribing protects clinicians against adverse consequences**

When discussing antibiotic prescription, clinicians used the language of protection against adverse consequences rather than of actively ‘curing’ patients of infections. Decisions to start or continue antibiotics were influenced by the perception that antibiotics were necessary to prevent patient deterioration and mortality from infections (quote 1, table 3). Continuing antibiotics, rather than stopping early, was perceived as necessary to prevent AMR (quote 2, table 3). If clinicians were more certain of whether a patient had a bacterial infection or if they felt the course was completed and the antibiotics had led to clinical improvement, most were confident to stop (or withhold further) antibiotics. However, a minority viewed prescribing antibiotics as necessary just in case, despite believing that they were not currently required (quotes 2–3, table 3).

**Antibiotic necessity: prescribing protects clinicians against adverse consequences**

Clinicians believed that prescribing antibiotics was necessary to protect themselves when retrospectively defending their decision. Under uncertainty, prescribing or continuing antibiotics was generally perceived to be most defensible. Some consultants recounted interrogations in the coroner’s court about why they stopped or did not prescribe antibiotics (quote 4, table 3). None described being questioned for starting or continuing antibiotics.

Prescribing consistent with particular policies was perceived as defensible. One frequently raised national policy was Sepsis Six, which states that if a patient is thought to be septic, clinicians must prescribe empiric antibiotics within an hour.31 Some clinicians thus felt pressured to start antibiotics urgently because they believed that this behaviour was the most defensible (quote 5, table 3). This 60 min target is also a National Institute for Health and Care Excellence quality standard.12

---

**Table 3 Supporting quotations for clinician perceptions theme**

<table>
<thead>
<tr>
<th>Subtheme</th>
<th>Supporting quotations</th>
</tr>
</thead>
</table>
| Necessity to protect patients                 | 1. “I mean she has already gone on meropenem. So, it might be that it was keeping something [infection] at bay. And then it has been stopped. And that infection has re-developed.” —P57, middle-grade trainee, hospital 3, VBI  
2. “I think a four days’ course of antibiotics is going to lead to resistance if anything because he’s not completed a full course […] In this situation there’s not really been a bug, so I think a seven-day minimum [course] would be appropriate.” —P22, middle-grade trainee, hospital 3, VBI  
3. “Maybe they’ve got a minor infection, it will self-resolve without any antibiotics, but maybe [with antibiotics] you’ll get an extra day or so where the patient is now considered safe for discharge. And so, you’ve accelerated the discharge and so there’s a whole process of flowing the patient through the hospital and progressing them. And ultimately not exposing them to an environment in which they are at risk of actually picking up a nosocomial infection.” —P43, consultant, hospital 1, VBI  |
| Necessity to protect clinicians               | 4. “One of the questions that I was grilled on in the Coroner’s court last Monday was ‘Why are we stopping antibiotics? If he had such a bad infection, why did we stop the antibiotics?’” —P28, consultant, hospital 1, FG  
5. “I don’t know if you’ve heard about the Sepsis Six […] if you decided not to start antibiotics, I don’t know where you would stand, I don’t think you would have a leg to stand on at all.” —P10, consultant, hospital 2, FG  |
| Antibiotic-related concerns not prioritised   | 6. “[…] when I have a patient, and the patient is deteriorating, I just focus on that patient. I don’t think, ‘What’s the impact of starting this or that antibiotic on the whole ecology of the unit?’ I don’t bother because, to be honest, my focus is that patient.” —P1, consultant, hospital 3, VBI  
7. “[…] we’re creating our own monster [antimicrobial resistance] because we’re throwing around antibiotics.” —P11, consultant, hospital 1, FG  
8. “I’d want them to have antibiotics. Despite the fact that there is this theoretical risk of resistance.” —P36, consultant, hospital 2, VBI  |
| Being brave vs being burnt                     | 9. “It can be, sometimes, more helpful to start with a more focused [narrower spectrum] antibiotic rather than muddle the picture with empirical antibiotics. But that takes a certain amount of bravery.” —P3, early-career trainee, hospital 1, VBI  
10. “So, I, my gut feeling, so I’m 70% certain he doesn’t need antibiotics now.” —P6, consultant, hospital 3, VBI  
11. “Maybe I’m not yet at the stage where I’d be brave enough to start nothing [no antibiotics]. I would like to be. I think we give far too many antibiotics. But I’m probably not at that stage yet. […] Probably, in this particular instance, I don’t think you’d be able to get away with not starting antibiotics at all. Because she’s become so unwell, she’s intubated. I think what makes you more brave in your decision-making is experience.” —P35, middle-grade trainee, hospital 2, VBI  
12. “There’s definitely cases where you’re brave until you’re burnt and then you stop being brave. And you only have to have one, I had one recently where I just didn’t spot it as being sepsis and the guy died overnight.” —P48, consultant, hospital 1, FG  |

FG, focus group; VBI, vignette-based interview.
Concerns about prescribing’s adverse consequences: AMR and antibiotic toxicity

Clinicians’ predominant concern was AMR; they were aware of resistance and valued protecting antibiotic choice and efficacy. Despite perceiving AMR as important, these concerns were over-ridden by perceptions of antibiotic necessity to protect the patient and the clinician (quote 6, table 3). AMR concerns were moderated by perceptions of personal responsibility and accountability. Clinicians saw antibiotics as preventing consequences for which they were immediately responsible, with safeguarding the patient perceived as the overriding priority. They saw preventing AMR as distal to this aim and less of an immediate priority. There was variation between clinicians regarding the importance of AMR in prescribing decisions for individual patients. Some doctors saw strong links between their own prescribing and AMR (quote 7, table 3), whereas a minority felt less personally responsible for AMR and doubted whether resistance would occur (quote 8, table 3).

Unlike AMR, antibiotic toxicity concerns were infrequent. Strikingly, 3 out of 35 clinicians raised antibiotic-related adverse effects in their VBI. The remainder did not mention potential antibiotic side effects as a decision-making consideration.

Balancing necessity and concerns: ‘being brave’ versus ‘being burnt’

In uncertainty, clinicians were motivated to prescribe antibiotics empirically to protect against undesirable consequences. Nonetheless, they also valued using antibiotics carefully to protect their unit’s ecology. In contrast to prescribing and continuing antibiotics when uncertain, clinicians referred to withholding and stopping potentially unnecessary antibiotics as ‘bravery’ (quote 9, table 3). Framing ‘conservative’ prescribing as bravery illustrates clinicians’ expectations of adverse consequences resulting from not prescribing; this language highlights clinicians’ strong beliefs about antibiotics’ necessity despite acknowledgement of antibiotic-related concerns.

Bravery was believed to improve with clinical experience. Consultants described a ‘gut feeling’ they used to make decisions (quote 10, table 3); trainees recognised bravery’s benefits but worried about possible consequences of not prescribing (quote 11, table 3).

Negative experiences may over-ride this bravery. Previously ‘being brave’ with antibiotics but experiencing negative consequences may stifle clinicians’ bravery with future patients (quote 12, table 3). ‘Being burnt’ appears to have motivated consultants to revert to prescribing or continuing antibiotics in future patients in uncertainty. Experiencing adverse personal consequences after not prescribing may strengthen antibiotic necessity perceptions, discouraging bravery in future decisions.

Contextual factors

The decision-making context moderated clinicians’ necessity and concerns perceptions. It could either reinforce or over-ride inclinations to prescribe in uncertainty. Contextual factors include decision-making in-hours versus out-of-hours, input from external team members and ICU prescribing norms.

Table 4 shows supporting quotations.

Decision-making in-hours versus out-of-hours

In-hours, clinicians felt more confident to withhold antibiotics in uncertainty. On weekdays, consultant intensivists typically made antibiotic decisions with clinical microbiology involvement. Early-career and middle-grade trainees reported having little input (quotes 13–14, table 4). In-hours decisions were seen as more judicious than out-of-hours decisions, with clinicians having higher thresholds to prescribe antibiotics during ‘core hours’ (quote 15, table 4).

For out-of-hours prescribing, consultants provide contingency ‘SOS plans’ for early-career and middle-grade trainees, to whom decision-making responsibility falls. If trainees felt confident, they could prescribe without input; otherwise, they were expected to contact on-call ICU and microbiology consultants. Some perceived variation in consultants’ expectations about being called and worried about disturbing them at night (quote 16, table 4).

If trainees felt unable to access consultant support, they were likely to start or continue antibiotics empirically. Many viewed prescribing antibiotics as ‘safest’, favouring broad-spectrum antibiotics which they believed were less risky than narrow spectrums (quote 17, table 4). These beliefs illustrate trainees’ strong necessity beliefs out-of-hours; they also anticipated that consultants would overturn inappropriate prescriptions in-hours (quote 14, table 4).

Input from external team members

Clinicians reported that external team members—generally clinical microbiologists and pharmacists—often increased intensivists’ confidence about withholding or stopping potentially unnecessary antibiotics. These ‘antimicrobial stewards’ would challenge potentially inappropriate antibiotic decisions, remind clinicians about local AMR rates and reach a consensus about antibiotics with consultant intensivists (quote 18, table 4). Consultant intensivists appreciated these negotiations and occasionally would await this input before making decisions.

There were some points of tension regarding clinical microbiology advice. As microbiologists did not usually examine patients, certain clinicians worried that microbiology recommendations relied on potentially inaccurate or incomplete information from ICU trainees (quote 19, table 4). Similarly, certain consultants expressed concerns that some trainees followed microbiology recommendations without checking
Table 4: Supporting quotations for contextual factors theme

<table>
<thead>
<tr>
<th>Subtheme</th>
<th>Supporting quotations</th>
</tr>
</thead>
</table>
| **Decisions in-hours vs out-of-hours** | 13. “Most antibiotic decisions are made by microbiology or the consultant rather than us. On the wards it’d be different, it’d be more us, but overhere everything’s passed on to someone more senior.” —P27, early-career trainee, hospital 1, VBI  
14. “I would like to use slightly less strong antibiotics, but I’m not allowed to. […] if you make the decision out-of-hours it’ll get changed backin-hours. It’s made by the consultants and they rely a lot on microbiology […] there’s very little independence in decision-making in an intensive careunit on a junior level.” —P35, middle-grade trainee, hospital 2, VBI  
15. “[…] during the day, there’s lots of bosses around, and you’d get to phone up micro, and there’d be someone on the micro ward round. Then you might be helped, you know might … the consultant might take the decision to be… to hold steady, wait for a bit longer, wait for theseresults to come back. And then take a decision. But if it was just down to skeleton crew, a couple of SHOs [early-career trainees] and the Reg.[middle-grade trainee], in the middle of the night, the three, after the consultant probably has gone to bed, the Reg. might take the decision thatactually we’re just going to [prescribe antibiotics].” —P3, early-career trainee, hospital 1, VBI  
16. “[…] you are always less likely to phone a consultant in the middle of the night, for advice because you are more worried about disturbingthem, […] it’s when you feel like you’re on your own and you can’t get it in touch with anyone else, that’s when I think you err on the side ofcaution and you prescribe [antibiotics].” —P25, middle-grade trainee, hospital 3, FG  
17. “[…] out-of-hours or what have you, when you haven’t got all of the support around decision making that you might want, your primary aimisto do something which is safest for the patient in front of you […] [which] is to give them the broadest spectrum [antibiotic] you can at thetime.” —P15, middle-grade trainee, hospital 3, VBI |
| **Input from external teams** | 18. “If you go on [Consultant Microbiologist’s] ward round and no one can, eh, say why the antibiotics, what it’s for, or when it’s going to stop, then that’s a good thing to challenge. And I think that probably has resulted in us shaving a few days of antibiotic usage and therefore, last year, achieving that [quality service initiative].” —P38, consultant, hospital 1, FG  
19. “[…]micro base it [antibiotics] on the information they’re given by the registrars and their decision will be as good as the information thatthey get.” —P10, consultant, hospital 2, FG  
20. “[Early-career and middle-grade trainees are] just happy to take opinions from other people and just do that and just say it was suggested byX, Y, and Z, and that’s why we’ve done it. So, I think we’ve actually lost our skills as clinicians […] If it’s something to do with nutrition, they saytell the dietician. If it’s something to do with antibiotics, tell the microbiologist.” —P8, consultant, hospital 4, VBI  
21. “I don’t feel that confident about getting the right antibiotic. I’d want to get micro involved.” —P57, middle-grade trainee, hospital 3, VBI  
22. “[…] it’s very rare that surgical prophylaxis will continue past 24 hours. There’s one particular gastro-intestinal surgeon who does five orseven days for his hepatectomies and stuff and try as we might we can’t get that stopped.” —P5, pharmacist, hospital 3, FG  
23. “It’s a bit of a consensus, isn’t it? We try hard not to have a massive fight. We try and persuade people. I wouldn’t go up to a haematologistvery often and insist they stopped all the antibiotics and say, well, even if you’re not, I’m going to. Well, you’re on my ward – that wouldn’t happen. It’s kind of well we think there’s no good reason, can we [stop antibiotics]?” —P48, consultant, hospital 1, FG  
24. “Most of the time, we’re fighting off external pressure to change – to either crank up or put two antibiotics or start them inappropriately. We’ve got lots of physicians that seem to think that everybody needs an antibiotic when there’s [something] wrong with them which we’ll resist quite strongly.” —P29, consultant, hospital 4, FG  
25. “[…] the trouble is if you stop the antibiotic on a haematology patient and something goes wrong, then you’re automatically in firing lines. So, I don’t think anybody does tend to.” —P17, microbiologist, hospital 1, FG  
| **ICU prescribing norms** | 26. “[…] here, there’s been a lot more of a push to get a clearer idea of the source before you start [antibiotics].” —P44, middle-grade trainee, hospital 1, VBI  
27. “[…] we’re really tightly controlled here for antibiotics. There isn’t much leeway, […] Co-amox [iclav] is in the corner [i.e., banned], we’re notallowed to touch it. […] you get a slap on the wrist if you deviate from the guidelines.” —P20, early-career trainee, hospital 4, VBI  
28. “[In this ICU] the use of antibiotics is far more widespread and so you would be against the grain if you didn’t use them. So, you would be notpart of normal practice.” —P54, middle-grade trainee, hospital 2, VBI  
29. “For me, at least, I would like to stop as soon as possible, for every antibiotic, especially if it was given empirically. I think many times we justcontinue antibiotics when it’s [sic] uncalled for.” —P23, middle-grade trainee, hospital 3, VBI  
30. “You have to go with your hospital protocol because it’s designed with your patient demographics in mind.” —P21, middle-grade trainee, hospital 3, VBI  
31. “There are some guidelines but they’re not really go-to guidelines for intensive care as they are on AMU [acute medical unit] and throughoutthe hospital. I think they’re a bit looser. I think it’s more individually decided upon. On the ward there are guidelines, but they are pretty mucheveryone follows that line unless you’ve got something very unusual. Whereas on ICU it’s not like we have a set of guidelines that we generallygo down that line.” —P51, consultant, hospital 1, FG |

FG, focus group; ICU, intensive care unit; VBI, vignette-based interview;

or understanding the rationale (quote 20, table 4). Trainees valued microbiology input, but some felt deskilled in their independent prescribing abilities because of this support (quotes 20–21, table 4).

Other external team members would forcefully advocate inappropriate decisions, which included starting, adding and continuing potentially unnecessary antibiotics. For instance, one surgeon would insist on multiple days of prophylaxis, although local practice was 24 hours (quote 22, table 4). Although ICU consultants had the ultimate decision, none reported over-ruling the external party. Rather, they would negotiate to encourage an appropriate decision (quote 23, table 4). Discussion outcomes varied—some successfully persuaded more appropriate decisions (quote 24, table 4), whereas others acquiesced to
external pressure because they feared possible consequences or were unable to convince resolute individuals (quotes 22 and 25, table 4).

ICU prescribing norms
Local norms influenced clinicians’ prescribing. These include informal norms referring to what clinicians believed was locally encouraged and prescribed, official institutional guidelines and AMS policies (table 1), and clinicians’ attitudes towards policies in terms of adhering to recommendations.

Consultants shaped informal norms and taught or modelled them to trainees. Following these norms and prescribing consistent with colleagues were believed to signal that one’s decisions were defensible. Thus, local norms likely affected anticipated interpersonal prescribing consequences and clinicians’ necessity perceptions of protecting themselves with prescriptions.

In hospitals 1 and 4, hasty empiric prescribing was discouraged in favour of identifying the source of infection before prescribing (quote 26, table 4). Hospitals 2 and 4 also banned certain broad-spectrum agents, aiming to prevent AMR development (quote 27, table 4).

Other informal norms arguably motivated suboptimal antibiotic practices. Middle-grade trainees in hospital 2 described patients receiving potentially unnecessary antibiotics, patients receiving broad-spectrum antibiotics than required, and an unwillingness to stop antibiotics until after a 5-day course. These trainees reported reluctantly following these norms; they would prefer to use fewer broad-spectrum antibiotics and to stop antibiotics sooner if patients had clinically improved (quotes 28–29, table 4).

Units also differed in attitudes towards institutional guidelines. Clinicians in hospitals 2, 3 and 4 believed guidelines must be followed, with consultants sometimes reprimanding guideline deviations. Conversely, hospital 1 clinicians believed that guidelines did not have to be strictly followed (quotes 27 and 30–31, table 4). Variation in adherence beliefs may result from whether clinicians saw guidelines as flexible enough to individualise patient care. Clinicians in units with strict adherence beliefs tended to see guidelines as sufficiently tailored for their patient population, whereas doctors in units with less stringent adherence norms tended to see guidelines as less tailored to individual patients.

DISCUSSION
This is the first study applying NCF to explain ICU antibiotic decision-making. Prescribing decisions were usually made in uncertainty and high stakes due to the significant consequences of antibiotic undertreatment and overtreatment.

Antibiotic decisions were influenced by clinicians’ perception of the necessity to prescribe relative to their concerns about the consequences of doing so. Necessity perceptions were strongly influenced by beliefs that antibiotics would protect patients from deterioration and clinicians from ethical, legal and reputational consequences of undertreatment. Similar beliefs were identified by a systematic review of determinants of hospital antibiotic prescribing.10

Consistent with previous studies,10 our participants commonly cited AMR as a concern. However, AMR was perceived as more distal relative to antibiotic necessity as proximal protection. Similarly, few clinicians identified antibiotic toxicity concerns as key decision-making contributors. Clinicians’ strong necessity beliefs and low concerns translated into favouring prescribing or continuing empiric antibiotics, termed ‘errring on the side of caution’.

A loss aversion bias may augment this inclination to prescribe. This heuristic is where subjective losses outweigh equivalent potential gains when there are perceived risks and uncertain outcomes, incentivising individuals to behave in a way that minimises their likelihood of experiencing penalties. Clinicians’ inclination to prescribe is thus understandable given the immediacy and severity of consequences associated with antibiotic undertreatment compared with those associated with overtreatment. Clinicians are also individually responsible for the consequences associated with undertreatment, whereas the consequences associated with overtreatment are collective. This finding is consistent with previous assertions that the severe consequences of undertreatment for individuals motivate hospital antibiotic overprescription.18

Context affected clinicians’ inclination to prescribe in uncertainty. Like prior research, prescribing in-hours versus out-of-hours,35 input from certain external team members36 and prescribing norms37 were perceived to influence decision-making. Similarly, prescribers’ capabilities,38 past experience39 and external policy40 may affect this behaviour (figure 1). Further research should explore the relationships between these factors.

A repeatedly stated view was that ‘complete antibiotic courses’ militated against resistance. While the view is valid (eg, in tuberculosis),41 it is questionable in the ICU where standard treatment courses (eg, for pneumonias) have been progressively shortened42 and early termination or de-escalation minimises selection pressure on gut flora, which (rather than the proximate infection) is the likely source of future resistance. If there is no pathogen, completing the course has no possible merit and may cause collateral harm.

Quality and safety recommendations
Clinicians’ perceptions of the proximal need for antibiotics appear to outweigh their antibiotic-related concerns, leading to favouring overprescription in uncertainty. This behaviour is understandable; however, inappropriate empiric antibiotics may increase the risk of death43 and may promote AMR.
Our participants recognised AMR’s threat; however, they viewed it as distal and did not prioritise it during decision-making.

Our findings have implications for AMS intervention development in ICUs. Interventions designed to increase AMR awareness are less likely to be effective than approaches that address clinicians’ necessity concerns evaluation when making prescribing decisions for individual patients. Our participants were concerned about distal AMR, yet prioritised their proximal need to protect against the consequences of not prescribing. Thus, interventions raising clinicians’ concerns about potential antibiotic-related harms to the patient are more likely to reduce antibiotic necessity perceptions than general AMR-related messages.

New technology may help reconcile clinicians’ beliefs about the necessity to prescribe/not prescribe. Molecular diagnostics can detect bacteria, viruses and antibiotic resistance genes within hours, rather than the 48–72 hours needed for laboratory culture. Having molecular diagnostic results may encourage clinicians to prescribe narrower-spectrum antibiotics than ordinarily used for empiric therapy, stop antibiotics if a virus and/or no bacterial pathogens are found, and de-escalate to narrow-spectrum antibiotics once a pathogen is identified. Nevertheless, given the potential consequences of undertreatment, clinicians may not trust negative results and may continue empiric antibiotics. In context, clinicians’ antibiotic necessity perceptions may explain findings of a lack of difference in intensivist prescribing with and without a highly sensitive rule-out test (ie, one advising discontinuing antibiotics because an infection was unlikely). Novel information may be insufficient to over-ride established decision-making beliefs; confidence in such systems and interventions increasing the defensibility of non-prescribing should be developed to encourage behaviour change.

Contextual factors can moderate the preference of erring on the side of caution. ICU consultants and micro-biologists should continue creating SOS plans to follow out-of-hours and should ensure these accord with AMS principles. Antimicrobial stewards may experience barriers to participation in antibiotic decision-making (eg, limited consultant contact); such obstacles should be assessed and addressed locally. Units should also create norms promoting AMS practices (eg, restricting specific broad-spectrum antibiotics).

Limitations
This study has limitations. VBIs are self-reports about clinicians’ prescribing intentions without real patient-related or clinician-related consequences. Therefore, participants may answer differently in vignette decisions from how they would have acted with actual patients (eg, in terms of withholding antibiotics).
While we intentionally designed vignettes with no correct answers to encourage reflection in uncertainty, future research using vignettes with ‘correct’ responses may better understand factors associated with inappropriate prescribing.

We investigated prescribing in English ICUs. We recognise that Hulscher and colleagues’ review included national culture, and that developing and developed nations have differing drivers to AMR development. More research should explore antibiotic decision-making in other cultural contexts, including the ‘open ICU’ model, where patients remain under the care of their primary physician or surgeon rather than intensivists; this model, which is nowhere followed in the UK, has less central control and has been associated with higher infection rates.

We sampled from four hospitals; staff may not fully represent English ICUs. However, these hospitals were selected to ensure diversity and participants would have trained at multiple institutions, so attitudes and behaviours would have evolved from a wider footprint.

Our focus groups included two microbiologists and one infectious disease doctor. Our focus was on ICU bedside clinician decision-making; future studies should explore specialist decision-making.

CONCLUSION
This is the first study exploring antibiotic decision-making in ICU using NCF. When making antibiotic decisions, clinicians must balance important consequences for the individual patient, themselves and the society, under high-stakes and uncertain conditions. Our findings indicate that clinicians favoured erring on the side of caution—prescribing or continuing empiric antibiotics in uncertainty to protect against possible consequences of undertreatment. Clinicians viewed antibiotics’ necessity (ie, protection for their patients and themselves) as outweighing concerns about antibiotic toxicity and AMR. Stewardship initiatives are more likely to be effective if they address clinicians’ perceptions of antibiotic necessity and increase concerns about antibiotics’ potential harmful effects for individual patients.

Author affiliations
1Centre for Behavioural Medicine, University College London, London, UK
2UCLH-UCL Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, UK
3Department of Psychological and Behavioural Science, London School of Economics and Political Science, London, UK
4Division of Critical Care, University College London Hospitals NHS Foundation Trust, London, UK
5Division of Infection and Immunity, University College London Hospitals NHS Foundation Trust, London, UK
6Norwich Medical School, University of East Anglia, Norwich, UK
7Department of Medical Microbiology, University College London Hospitals NHS Foundation Trust, London, UK
8Department of Surgery and Cancer, Imperial College London, London, UK

Acknowledgements We would like to thank all ICU staff who were involved in organising or participating in the research. We also thank Norwich Clinical Trials unit and our Patient and Public Involvement group. This research is supported by researchers and infrastructure at the National Institute for Health Research University College Hospitals and Imperial Biomedical Research Centres. YJ is a Health Foundation Improvement Science Fellow.

Collaborators INHALE WP2 Study Group; authors and their affiliations as above; and Julie Barber and Laura Shallcross, University College London; Jeronimo Cuesta, North Middlesex Hospital; Mark Peters and Nigel Klein, Great Ormond St Hospital and UCL Great Ormond St Institute of Child Health NIHR Biomedical Research Centre; Parvez Moondi, Norfolk and Norwich University Hospitals NHS Foundation Trust; Justin O’Grady, Quadram Institute and University of East Anglia; Juliet High, Charlotte Russell and David Turner, Norwich Clinical Trials Unit, University of East Anglia; and Suveer Singh, Chelsea and Westminster Hospital NHS Foundation Trust.

Contributors This study was conceptualised and designed by RH, SJF, TWR, DB, VIE, DML and VG. Vignettes and interview guides were written by SJF, DB and TWR. Focus groups and interviews were conducted by NB and YJ. Data were analysed by AMP and NB, with input from YJ, SJF, TWR and RH. The manuscript was written by AMP, with input from the remaining authors.

Funding This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Reference Number: RP-PG-0514-20018). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care.

Competing interests VIE reports personal fees and non-financial support from bioMerieux, personal fees from Curetis and non-financial support from Oxford Nanopore Technologies, outside the submitted work. DML reports personal fees from Accelerate, Allegra, Antabio, Astellas, Beckman Coulter, bioMerieux, Cepheid, Centauri, Entas, Johnson & Johnson, Meiji, Melinta, Menarini, Mutabils, Nordic, ParaPharm, QPEX, Roche, Shionogi, Tetrabase, Wockhardt, Zambon, Cardiome and Eumedica. He also reports grants and personal fees from VenatoRx; personal fees and other (shareholder) from GlaxoSmithKline; personal fees and other (stock options) from TAZ; grants, personal fees and other (shareholder) from Merck MSD and Pfizer; and other (shareholder) from Perkin Elmer and Dechra. All are outside the submitted work.

Patient consent for publication Not required.

Ethics approval This research received ethical approval from the Camden and Kings Cross Research Ethics Committee (16/LO/1618).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different
terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ID
Alyssa M Pandolfo http://orcid.org/0000-0003-0455-496X

REFERENCES


Supplementary table S1: Focus group topic guide

1. What factors influence the decisions around AM [antimicrobial] prescribing on ICU [intensive care unit] in this Trust [i.e., institution]/hospital?

Prompts (if not mentioned spontaneously):

- How do the AM stewardship programmes in the Trust affect AM prescribing decisions? What are your thoughts on the AM stewardship programmes within the Trust?

- What infrastructure is there to support AM prescribing on the ICU? *E.g. laboratory support, electronic prescribing*

- How does experience and expertise of staff influence the AM prescribing decisions? *E.g. Intuitional versus analytical decision making, confidence in prescribing*

- How does the organisational culture impact on AM prescribing decisions? *E.g. hierarchy, prescribing autonomy, transparency, general compliance with guidelines, general use of AM (culture of broad spectrum overuse?)*

- How do individual patient factors which influence the AM prescribing decisions? *E.g. comorbidities, antibiotic history, allergies, provenience, severity of illness/risk of deterioration*

- How does perceived patient risk affect AM prescribing? *E.g. risk of ineffective treatment, risk of AE [adverse events] and Interactions, distal versus proximal risk?*

- What effect do local resistance patterns have on AM prescribing? How is this affected by the type of infection? *E.g. HAP or VAP*

- How does the time of day/ day of week affect the decision making process?

- How do interactions between different teams (ICU, micro[biology], ID [infectious diseases], specialist) affect AM prescribing decisions? *E.g. communication, collaboration, conflict resolution*

- How do prescribing etiquette and hierarchy affect AM prescribing decisions? *E.g. feedback on colleagues prescribing? Pressure to comply with decisions? Level of seniority?*

2. Are there any factors that we haven’t discussed today that you think affect AM prescribing decisions on ICU?
Supplementary table S2: Vignettes and interview guides

### Scenario 1: A starting vignette (Adult)

Frieda is 55yo [years old] and was admitted to your ICU [intensive care unit] 10 days ago with acute, severe pancreatitis. She has suffered in the past from gall stones but apart from intermittent pain they caused her no other problems. However, 12 days ago she presented to the ED [emergency department] with very severe abdominal pain and a diagnosis of (necrotising) pancreatitis was confirmed by a CT [computerised tomography] scan and a markedly raised amylase. Following admission she deteriorated on the ward with increasing abdominal distension, progressive cardiovascular and respiratory deterioration. She required intubation and ventilation and, for 48 hours required noradrenaline. She was started on a course of meropenem and TPN [total parenteral nutrition] (intravenous food) via a central line at the time of intubation. Otherwise management was conservative.

10 days later and things are improving, she is no longer on vaso-actives, her abdomen is less distended and NG [nasogastric] aspirates are decreasing, though the surgeons still feel TPN is warranted. She remains intubated but is slowly weaning from the ventilator (FiO2 [fraction of inspired oxygen] 0.45, PSV [pressure support ventilation] 15/7) she is slowly waking up as the sedation is reduced. The meropenem was stopped 3 days ago.

You are covering the ICU tonight and the nurse at the bedside reports she has a new temperature of 38.1C. The chart shows no other temperatures over the last 4 days. There was nothing unusual about her morning bloods (CRP [C-reactive protein]/WCC [white cell count], raised but stable etc.). She is also a bit more tachycardic, normally ~90bpm [beats per minute], now ~100bpm but blood pressure is maintained, urine output seems good and no change to her respiratory parameters or blood gas.

Her CVC [central venous catheter] looks clean, the abdomen is distended and appears tender on palpation (though no more than last night), and she has decreased air entry at both bases with occasional coarse crackles.

### Scenario 1: A starting vignette (Paediatric)

Amber is an 11 month old admitted to your ICU with respiratory distress. She had been unwell for 48 hours with a mild temperature, cough and fast breathing. She was seen in A and E [Accident and Emergency] at her local hospital and referred to [Hospital name] for concerns about breathing. Her respiratory distress worsened and her oxygen Sats [saturation] started to decline following arrival on PICU [paediatric intensive care unit]. She had bilateral crackles and wheezes. An NPA [nasopharyngeal airway] from the referring hospital revealed RSV [respiratory syncytial virus]. The Intensivists felt she required intubation and ventilation. A CXR [chest X-ray] showed some patchy shadowing. She has a fever of 38.5 C. Her CRP [C-reactive protein] is 22.

### Interview schedule for starting vignettes

1. What is going through your mind here?
2. Would you start antibiotics?
3. How comfortable are you with your decision?
4. If you are not 100% sure you are doing the right thing what information would you like (either existing tests or one from the future)?
5. If you had a device able to detect respiratory pathogens in 6 hours, would that change your approach (or levels of comfort)?
6. Does antimicrobial stewardship factor into your prescribing decisions? In what ways?

---

1 An analysis of responses to questions 4 and 5 will be published in a separate manuscript.
### Scenario 2: A stopping/de-escalating vignette (Adult)

You have just taken over the care of John. He is 73 years old and was admitted with a fractured neck of femur. He has a history of moderate COPD [chronic obstructive pulmonary disease] but continues to smoke 15-20 cigarettes/day. His symptoms are managed by his GP [general practitioner] using a combination of inhalers, allowing him to be independent; he has never been in hospital before. The fracture was successfully operated on the next day. John was slow to mobilise, and after three days he started to feel generally unwell, increasingly short of breath and developed a cough productive of yellow sputum. He was reviewed on the ward by the medical team, and started on appropriate antibiotics. However, he continued to worsen. When he was reviewed the next day, he was noted to be very tachypnoeic (35/minute) and hypoxic (PaO2 [partial pressure of oxygen] 6.4kPa on FiO2 [fraction of inspired oxygen] 0.6). He had a heart rate of 110 and a temperature of 37.9°C. There were some crackles heard at his right lung base and a widespread, fine, expiratory wheeze. His white cell count was 12x10^9/ml (neutrophilia) and his CRP [C-reactive protein] was 64mg/l (normal 0-5). A chest X-ray demonstrates clear consolidation/collapse of the right middle lobe. A diagnosis of hospital acquired pneumonia was made. He was transferred to the ICU [intensive care unit], where he was intubated and ventilated.

4 days later you take over his care on the ICU. He is slowly weaning from ventilation, he has had an occasional low grade pyrexia (37.7 max), his CRP is falling (22) and WCC [white cell count] remains slightly elevated at 13x10^9/ml. An endotracheal aspirate was sent for culture soon after admission to the ICU but so far, no growth. Blood cultures, the atypical screen, Influenza A/B PCR [polymerase chain reaction] and pneumococcal ag [antigen test] also remain negative. No other concerns have been raised.

### Interview schedule for stopping/de-escalating vignettes

1. What would you like to do with the antibiotics? Please explain your rationale.
   - Stop?
   - Continue until:
     - End of course?
     - CRP [C-reactive protein] and WCC [white cell count] normalised?
     - Patient is extubated?
2. How comfortable are you with this decision?
3. What further evidence would you like?
4. Does antimicrobial stewardship factor into your prescribing decisions? In what ways?

### Scenario 2: A stopping/de-escalating vignette (Paediatric)

Peter, a 2-year old born prematurely at 24 weeks with chronic lung disease had been admitted to PICU [paediatric intensive care unit] on 4 occasions with respiratory distress. Now he is 2 years old and was admitted a week ago (In December) with respiratory distress. The CXR [chest X-ray] showed some increased shadowing but on a background of chronic lung disease. An NPA [nasopharyngeal airway] had revealed RSV [respiratory syncytial virus] and Influenza B when admitted. He was started on Piperacillin/Tazobactam and Amikacin for suspected secondary bacterial chest infection. Tracheal aspirates grew commensals. He started to improve and is due to be weaned from the ventilator over the next 24 hours. His CRP [C-reactive protein] is 29.
Supplementary table S3: Authors’ disciplines

AMP is a research psychologist, with a specialisation in organisational and social psychology.

RH is a professor in behavioural medicine.

YJ is a consultant pharmacist with experience in qualitative research and interviewing.

TWR is an associate professor in organisational psychology.

NB has a background in clinical pharmacy and has experience in research in behavioural medicine, including qualitative research and interviewing.

DB is a consultant intensivist at one of the participating sites.

VIE is a senior research fellow in microbiology.

DML is a professor in medical microbiology.

VG is a consultant in microbiology and infection at two of the participating sites.

SJB is a professor of critical care medicine and a consultant intensivist at a non-participating hospital. Before data collection, he believed that interviewees would discuss their confidence about different sources of advice or information available.